One of the Cox-2 inhibitors.

The FDA cited "potential increased risk for serious cardiovascular (CV) adverse events," an "increased risk of serious skin reactions" and the "fact that Bextra has not been shown to offer any unique advantages over the other available NSAIDs.

Which is the problem with the entire class, and the pharmaceutical industry at large. They keep doing this, releasing new drugs that aren't an improvement on old drugs to make more money. It doesn't end here.